Aclaris Therapeutics Inc (NASDAQ: ACRS) on Friday, soared 3.82% from the previous trading day, before settling in for the closing price of $1.57. Within the past 52 weeks, ACRS’s price has moved between $1.05 and $5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 15.24% over the past five years. The company achieved an average annual earnings per share of 69.51%. With a float of $92.29 million, this company’s outstanding shares have now reached $108.33 million.
Let’s look at the performance matrix of the company that is accounted for 64 employees. In terms of profitability, gross margin is 20.55%, operating margin of -791.9%, and the pretax margin is -732.42%.
Aclaris Therapeutics Inc (ACRS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Aclaris Therapeutics Inc is 14.81%, while institutional ownership is 76.15%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares.
Aclaris Therapeutics Inc (ACRS) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.11 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.01) by -0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.41% during the next five years compared to 15.24% growth over the previous five years of trading.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Aclaris Therapeutics Inc (ACRS) is currently performing well based on its current performance indicators. A quick ratio of 3.88 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.37, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.54 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics Inc (NASDAQ: ACRS) saw its 5-day average volume 0.64 million, a negative change from its year-to-date volume of 0.98 million. As of the previous 9 days, the stock’s Stochastic %D was 30.88%.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 71.66%, which indicates a significant increase from 42.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1073 in the past 14 days, which was higher than the 0.1012 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5318, while its 200-day Moving Average is $1.9923. Nevertheless, the first resistance level for the watch stands at $1.6632 in the near term. At $1.6964, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7430. If the price goes on to break the first support level at $1.5834, it is likely to go to the next support level at $1.5368. The third support level lies at $1.5036 if the price breaches the second support level.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
Market capitalization of the company is 176.58 million based on 108,281K outstanding shares. Right now, sales total 18,720 K and income totals -132,070 K. The company made 1,460 K in profit during its latest quarter, and -15,090 K in sales during its previous quarter.
